Associated Papers
Integrated multi-omics analysis reveals the involvement of the gut-brain axis in children with autism.
Zhong H et al.
Frontiers in Microbiology, 2026
The pharmacogenomic landscape in the Chinese: An analytics of pharmacogenetic variants in 206,640 individuals.
Wang LY et al.
Innovation (cambridge (mass.)), 2025
ACE Phenotyping in Human Blood and Tissues: Revelation of ACE Outliers and Sex Differences in ACE Sialylation.
Enyedi EE et al.
Biomedicines, 2024
Immunogenomic analysis of human brain metastases reveals diverse immune landscapes across genetically distinct tumors.
Álvarez-Prado ÁF et al.
Cell Reports. Medicine, 2023
Validating Amino Acid Variants in Proteogenomics Using Sequence Coverage by Multiple Reads.
Levitsky LI et al.
Journal of Proteome Research, 2022
Association between DCK 35708 T>C variation and clinical outcomes of acute myeloid leukemia in South Chinese patients.
Zhang DY et al.
Pharmacogenomics, 2016
Exome-based proteogenomics of HEK-293 human cell line: Coding genomic variants identified at the level of shotgun proteome.
Lobas AA et al.
Proteomics, 2016
The clinical implication of single nucleotide polymorphisms in deoxycytidine kinase in chronic hepatitis B patients treated with lamivudine.
Lee HW et al.
Journal of Medical Virology, 2016
dCK Expression and Gene Polymorphism With Gemcitabine Chemosensitivity in Patients With Pancreatic Ductal Adenocarcinoma: A Strobe-Compliant Observational Study.
Xiong J et al.
Medicine, 2016
Acquisition of chemoresistance to gemcitabine is induced by a loss-of-function missense mutation of DCK.
Nakano T et al.
Biochemical and Biophysical Research Communications, 2015
Impact of single nucleotide polymorphisms of cytarabine metabolic genes on drug toxicity in childhood acute lymphoblastic leukemia.
Gabor KM et al.
Pediatric Blood & Cancer, 2015
Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in cytidine deaminase and deoxycytidine kinase.
Baker JA et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2013
The influence of gemcitabine pathway polymorphisms on treatment outcome in patients with malignant mesothelioma.
Erčulj N et al.
Pharmacogenetics and Genomics, 2012
Pharmacogenetics and pharmacoepigenetics of gemcitabine.
Candelaria M et al.
Medical Oncology (northwood, London, England), 2010
Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms.
Sugiyama E et al.
Clinical Pharmacokinetics, 2010
Homozygous CDA*3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patients.
Ueno H et al.
British Journal of Cancer, 2009
Gemcitabine pharmacogenomics: deoxycytidine kinase and cytidylate kinase gene resequencing and functional genomics.
Kocabas NA et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2008
Twenty novel genetic variations and haplotype structures of the DCK gene encoding human deoxycytidine kinase (dCK).
Kim SR et al.
Drug Metabolism and Pharmacokinetics, 2008
Pharmacogenetics of deoxycytidine kinase: identification and characterization of novel genetic variants.
Lamba JK et al.
The Journal of Pharmacology and Experimental Therapeutics, 2007
Novel deoxycytidine kinase gene polymorphisms: a population screening study in Caucasian healthy volunteers.
Joerger M et al.
European Journal of Clinical Pharmacology, 2006